Weight-centric treatment of type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: Chronic non-communicable diseases (CNCD) represent a major cause of morbidity and mortality. Type 2 diabetes mellitus (T2DM) is one of the most prevalent CNCD that is associated with a significant medical and economic burden. One of the main modifiable risk factors of T2DM is obesity. Many medications used for T2DM can lead to weight gain, worsening one of the root causes of this disease. Methods: In this clinical review, we study the effect of medications for T2DM on body weight. We used MEDLINE, Google scholar, PubMed, Scopus, and Embase databases to search for relevant studies between 1 January 1950 to 20 September 2022 in English language. Here, we review the most prescribed medications for T2DM and summarize their effect on patients' body weight. We will also present an expert opinion on a recommended weight-centric approach to treat T2DM. Results: Multiple T2DM medications have been associated with weight gain. Insulin, sulfonylureas, thiazolidinediones and meglitinides may increase body weight. However, biguanides (e.g., metformin), glucagon-like peptide-1 agonists (e.g., semaglutide, liraglutide, tirzepatide), sodium-glucose cotransporter 2 inhibitors, and amylin analogs (e.g., pramlintide) are associated with significant weight loss. Dipeptidyl peptidase-4 inhibitors are considered weight neutral medications. Experts in the fields of endocrinology and obesity recommend utilizing a weight-centric approach when treating T2DM. Conclusion: Considering the high prevalence and debilitating complication of T2DM, it is of utmost importance to shift from a weight gain approach (i.e., insulin, sulfonylureas) into a weight loss/neutral one (i.e., GLP-1 agonists, SGLT-2 inhibitors, metformin).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In an RCT evaluating this medication, the TBWL % associated with tirzepatide 5 mg was 15.0%, tirzepatide 10 mg was 15.9%, and tirzepatide 15 mg was 20.9% (p 0.001 for all comparisons with placebo) [100].”
BackgroundInfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · cited 6×
“It results in the greatest reduction in HbA1c of up to 3.5% compared to other diabetes medications; however, it results in signi fi cant weight gain [54].”
BackgroundInfluentialPoirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“Tirzepatide has been shown to decrease HbA1c by 2.01, 2.24, and 2.3% with 5 mg, 10 mg, and 15 mg weekly doses, respectively [99].”
BackgroundInfluentialChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
The Diabetes Prevention Program (DPP)
The Diabetes Prevention Program (DPP) Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2165 · Cited by 1,938
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Bennett, J. E., Stevens, G. A., Mathers, C. D., Bonita, R., Rehm, J., Kruk, M. E., Riley, L. M., Dain, K., Kengne, A. P., Chalkidou, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31992-5 · Cited by 1,336 · cited 1×
“%) can be attributed to cancers, chronic cardiovascular and respiratory diseases, and type-2 diabetes mellitus (T2DM) [1].”
BackgroundPi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025 · cited 1×
“Similarly, obesity is considered a major risk factor for developing T2DM [8,9].”
Background
Cited by
Ghusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
Self-citationWeight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Ghusn, W., Fansa, S., Anazco, D., Tama, E., Nicolalde, B., Gala, K., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., et al. (2024) · International Journal of Obesity · doi:10.1038/s41366-023-01456-5 · Cited by 35
Self-citationAbi Mosleh, K., Salameh, Y., Ghusn, W., Jawhar, N., Mundi, M. S., Collazo‐Clavell, M. L., Kendrick, M. L., & Ghanem, O. M. (2024) · Clinical Obesity · doi:10.1111/cob.12689 · Cited by 5
“On the other hand, improvement in HbA1c was considerably higher in patients with insulin-treated T2D, with a drop from 7.7 ± 1.3% at baseline to 6.3 ± 1.1% during the first postoperative year, and remained relatively constant at 5-year follow-up at 6.7 ± 1.2% ( p < .001; Figure 3B ) .”
InfluentialSelf-citation
Metadata
- Authors
- Ghusn, W., Hurtado, M. D., & Acosta, A.
- Venue
- Obesity Pillars
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 4
- Pages
- 100045
- ISSN
- 2667-3681 (ISSN-L)
- OpenAlex
- W4309874918
- Cited by
- 40
- References
- 32
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight-centric treatment of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1016/j.obpill.2022.100045
- The paper
- Ghusn, W., Hurtado, M. D., & Acosta, A. (2022). Weight-centric treatment of type 2 diabetes mellitus. Obesity Pillars. https://doi.org/10.1016/j.obpill.2022.100045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.